CIRM Funded Clinical Trials

Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients


Disease Area:
HIV-related Lymphoma, HIV/AIDS
Investigator:
CIRM Grant:
CLIN2-08289 (Active)
Award Value:
$8,414,265.00
Trial Stage:
Phase 1/2
Trial Status:
Active, not recruiting
Targeted Enrollment:
11
ClinicalTrials.gov ID:

Details:

A team at UC Davis is taking a patient’s blood forming stem cells and inserting three anti-HIV genes into them and then returning them to the individual to help rebuild their immune system. The anti-HIV genes are then passed on to all new¬†immune system cells, which¬†makes them resistant to HIV. Because AIDS-related lymphoma is linked to the constant immune cell stimulation caused by HIV infection, getting rid of the virus should prevent return of the cancer.

Design:

Open label, single arm study.

Goal:

Safety. Efficacy - immune reconstitution, viral load and HIV status.

Contact Trial Sponsor

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov